Skip to main content
SpringerLink
Log in

Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report

  • Short Communication
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Candida endocarditis represents a life-threatening infection with high mortality rates despite adequate antifungal treatment. Step-down oral treatment with fluconazole or voriconazole represents a treatment option for clinically stable patients. Drug toxicity, however, is reported during azole therapy and can be challenging, especially among patients with multiple comorbidities. This is the first report that highlights the impact of isavuconazole on the corrected QT interval and liver toxicity in a cirrhotic patient with Candida endocarditis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Lefort A, Chartier L, Sendid B, et al; On behalf of the French Mycosis Study Group. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18(4):E99–E109.

  2. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50.

    Article  Google Scholar 

  3. Allen D, Wilson D, Drew R, et al. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev Antiinfect Ther. 2015;13:787–98.

    Article  CAS  Google Scholar 

  4. Weiler S, Zoller H, Graziadei I, et al. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother. 2007;9:3459–60.

    Article  Google Scholar 

  5. Keirns J, Desai A, Kowalski D, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101:782–90.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Division, Santa Maria della Misericordia University Hospital, Udine, Italy

    Elda Righi, Alessia Carnelutti & Matteo Bassetti

  2. Department of Cardiology, Santa Maria della Misericordia University Hospital, Udine, Italy

    Daniele Muser

  3. Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital, University of Udine, Udine, Italy

    Federico Pea

  4. Department of Medicine, University of Udine, Udine, Italy

    Federico Pea

  5. Division of Microbiology, Santa Maria della Misericordia University Hospital, Udine, Italy

    Assunta Sartor

Authors
  1. Elda Righi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Muser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessia Carnelutti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Federico Pea
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Assunta Sartor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matteo Bassetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elda Righi.

Ethics declarations

Informed consent

Informed written consent was obtained from the patient for the publication of this case report.

Conflict of interest

All authors declare that they have no potential conflicts of interest.

Funding

No specific funding was received.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Righi, E., Muser, D., Carnelutti, A. et al. Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report. Drugs Ther Perspect 34, 402–403 (2018). https://doi.org/10.1007/s40267-018-0520-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0520-4

Search

Navigation